Novartis AG ROA 2010-2022 | NVS

Current and historical return on assets (ROA) values for Novartis AG (NVS) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Novartis AG ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-06-30 $22.98B $122.91B 18.34%
2022-03-31 $24.18B $125.22B 19.26%
2021-12-31 $24.02B $131.80B 19.26%
2021-09-30 $9.81B $121.21B 7.93%
2021-06-30 $8.98B $124.02B 7.14%
2021-03-31 $7.96B $121.75B 6.33%
2020-12-31 $8.07B $127.78B 6.40%
2020-09-30 $7.10B $129.68B 5.74%
2020-06-30 $7.21B $123.76B 5.99%
2020-03-31 $12.14B $123.10B 10.25%
2019-12-31 $11.73B $118.37B 9.60%
2019-09-30 $11.80B $115.97B 9.15%
2019-06-30 $11.38B $116.29B 8.39%
2019-03-31 $12.35B $137.95B 8.69%
2018-12-31 $12.61B $145.56B 8.91%
2018-09-30 $13.39B $142.99B 9.68%
2018-06-30 $13.85B $142.06B 10.15%
2018-03-31 $8.06B $135.52B 6.00%
2017-12-31 $7.70B $133.08B 5.77%
2017-09-30 $6.68B $134.97B 5.04%
2017-06-30 $6.54B $133.75B 4.94%
2017-03-31 $6.37B $131.99B 4.83%
2016-12-31 $6.71B $130.12B 5.08%
2016-09-30 $6.81B $134.01B 5.14%
2016-06-30 $6.76B $131.44B 5.12%
2016-03-31 $6.79B $132.45B 5.10%
2015-12-31 $17.78B $131.56B 13.30%
2015-09-30 $18.22B $132.93B 13.79%
2015-06-30 $19.56B $135.41B 15.01%
2015-03-31 $20.27B $134.94B 15.86%
2014-12-31 $10.21B $125.39B 8.14%
2014-09-30 $10.75B $125.38B 8.55%
2014-06-30 $9.76B $125.77B 7.78%
2014-03-31 $9.72B $125.33B 7.82%
2013-12-31 $9.18B $126.25B 7.45%
2013-09-30 $9.13B $124.59B 7.44%
2013-06-30 $9.29B $121.07B 7.62%
2013-03-31 $9.42B $121.01B 7.77%
2012-12-31 $9.27B $124.19B 7.67%
2012-09-30 $8.29B $121.22B 6.95%
2012-06-30 $8.36B $118.49B 7.01%
2012-03-31 $8.42B $119.41B 6.95%
2011-12-31 $8.94B $117.50B 7.27%
2011-09-30 $10.11B $121.38B 8.12%
2011-06-30 $9.92B $125.92B 7.92%
2011-03-31 $9.63B $127.22B 8.16%
2010-12-31 $9.79B $123.32B 8.89%
2010-09-30 $9.93B $124.63B 9.62%
2010-06-30 $9.75B $96.92B 10.30%
2010-03-31 $9.37B $95.80B 10.23%
2009-12-31 $8.40B $95.51B 9.64%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $192.828B $52.877B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $447.434B 17.03
Eli Lilly (LLY) United States $287.922B 36.51
Pfizer (PFE) United States $279.310B 8.19
AbbVie (ABBV) United States $247.976B 10.54
Novo Nordisk (NVO) Denmark $236.707B 31.22
Merck (MRK) United States $226.779B 11.84